EML4 and neoplasm: Since FISH has been approved as a reliable diagnostic test for crizotinib (ALK inhibitor) treatment [32], our findings might suggest that high abundance of EML4-ALK positive cells in tumor tissues could also be related to the treatment response to ALK inhibitors.